Clinical Trial

CERvical Cancer The InFlammatory Index (CERTIFIKO)

Study acronym: CERTIFIKO
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
Although significant advances in screening and treatment , cervical cancer is the fifth most common female cancer in Europe. Major prognostic factors for oncological outcome are used to categorise patients at high, intermediate and low risk groups and to define the type of radical hysterectomy according "Querleu-Morrow classification". The goal of this prospective observational study is to evaluate the association between several inflammatory markers and risk groups according European guidelines in women with cervical cancer Human Papillomavirus (HPV)-associated, in order to optimize the treatment.
Trial Details
NCT Number NCT05673252
Lead Sponsor University of Campania Luigi Vanvitelli
Conditions Cervical Cancer
Enrollment 128 participants
Start Date 2023-07-18
Primary Completion 2025-12-18 (estimated)
Study Completion 2027-11-18 (estimated)
Updated on ClinicalTrials.gov 2026-08-07